Zolbetuximab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Zolbetuximab. Educational only — not medical advice.
Labeled uses
VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration (2.1 ) and Clinical Studies (14 )].
Source: FDA labeling via NIH DailyMed (set e7695a21…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.